依那西普治疗非全身型幼年特发性关节炎的近期疗效及安全性观察

The observation of short-term efficacy and safety of etanercept in treatment of non-systemic juvenile idiopathic arthritis

目的观察依那西普治疗非全身型幼年特发性关节炎的疗效和安全性。方法对30例非全身型幼年特发性关节炎患儿皮下注射依那西普0.4 mg/(kg.次),每周2次,在治疗后1周、1个月及3个月采用ACRPedi 30/50/70评分进行疗效评估。结果治疗后1周、1月及3月时ACR Pedi 30达标率分别为16.70%、90.00%、96.67%,ACR Pedi 50达标率分别为3.30%、30.00%、66.70%,ACR Pedi 70达标率分别为0、0、16.70%(5),且无重大不良事件发生。结论依那西普治疗非全身型幼年特发性关节炎具有较好的近期疗效,在病程早期使用效果更显著,不良反应小且发生率低。

Objective To observe the short-term clinical efficacy and safety of etanercept in treatment of non-systemic juvenile idiopathic arthritis（JIA）.Methods Thirty patients with non-systemic JIA were subcutaneously injected with etanercept 0.4 mg/kg twice a week.Clinical efficacy was evaluated based on ACR pedi 30/50/70 score 1 week,1 month,3 months after treatment.Results One week,1 month and 3 months after treatment,the ACR Pedi 30 compliance rates were 16.70%（5）,90.00%（27）and 96.67%（29）,ACR Pedi 50 compliance rates were 3.30%（1）,30.00%（9）and 66.70%（20）,and ACR pedi 70 compliance rates were 0,0 and 16.70%（5）.Meanwhile no significant adverse event happened.Conclusions Etanercept has a favorable short-term effect in treatment of non-systemic JIA.The clinical efficacy is more significant in early course of disease.The adverse events are few and minor.